Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A simple algorithm with one flow cytometric MRD measurement identifies more than 40% of children with ALL who can be cured with low-intensity therapy. The ALL-MB 2008 trial results.
Popov A, Henze G, Roumiantseva J, Budanov O, Belevtsev M, Verzhbitskaya T, Boyakova E, Movchan L, Tsaur G, Fadeeva M, Lagoyko S, Zharikova L, Miakova N, Litvinov D, Khlebnikova O, Streneva O, Stolyarova E, Ponomareva N, Novichkova G, Fechina L, Aleinikova O, Karachunskiy A. Popov A, et al. Among authors: karachunskiy a. Leukemia. 2022 May;36(5):1382-1385. doi: 10.1038/s41375-022-01542-z. Epub 2022 Mar 23. Leukemia. 2022. PMID: 35322171 No abstract available.
Results of the first randomized multicentre trial on childhood acute lymphoblastic leukaemia in Russia.
Karachunskiy A, Herold R, von Stackelberg A, Miakova N, Timakow A, Mahortih T, Bajdun L, Maschan A, Fechina L, Shamardina A, Dudkin S, Lebedev V, Varfolomeeva S, Timofeeva V, Roumiantseva J, Chipsanova N, Rumjanzew A, Henze G. Karachunskiy A, et al. Leukemia. 2008 Jun;22(6):1144-53. doi: 10.1038/leu.2008.63. Epub 2008 Mar 27. Leukemia. 2008. PMID: 18368070 Clinical Trial.
Efficacy and toxicity of dexamethasone vs methylprednisolone-long-term results in more than 1000 patients from the Russian randomized multicentric trial ALL-MB 2002.
Karachunskiy A, Roumiantseva J, Lagoiko S, Bührer C, Tallen G, Aleinikova O, Bydanov O, Korepanova N, Bajdun L, Nasedkina T, von Stackelberg A, Novichkova G, Maschan A, Litvinov D, Myakova N, Ponomareva N, Kondratchik K, Fechina L, Streneva O, Judina N, Scharapova G, Shamardina A, Gerbek I, Shapochnik A, Rumjanzew A, Henze G; ALL-MB study group. Karachunskiy A, et al. Leukemia. 2015 Sep;29(9):1955-8. doi: 10.1038/leu.2015.63. Epub 2015 Mar 9. Leukemia. 2015. PMID: 25748686 No abstract available.
The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia: literature review and own experience.
Dyakonova YY, Bydanov OI, Popov AM, Olshanskaya YV, Boichenko EG, Aleynikova OV, Maschan MA, Shelikhova LN, Litvinov DV, Khachatryan LA, Ponomareva NI, Fechina LG, Novichkova GA, Pashanov ED, Karachunskiy AI. Dyakonova YY, et al. Among authors: karachunskiy ai. Ter Arkh. 2018 Aug 17;90(7):38-50. doi: 10.26442/terarkh201890738-50. Ter Arkh. 2018. PMID: 30701921 Review.
Absolute count of leukemic blasts in cerebrospinal fluid as detected by flow cytometry is a relevant prognostic factor in children with acute lymphoblastic leukemia.
Popov A, Henze G, Verzhbitskaya T, Roumiantseva J, Lagoyko S, Khlebnikova O, Streneva O, Bidanov O, Tsaur G, Inaba H, Karachunskiy A, Fechina L. Popov A, et al. Among authors: karachunskiy a. J Cancer Res Clin Oncol. 2019 May;145(5):1331-1339. doi: 10.1007/s00432-019-02886-3. Epub 2019 Mar 6. J Cancer Res Clin Oncol. 2019. PMID: 30840196
Reduced vs. standard dose native E. coli-asparaginase therapy in childhood acute lymphoblastic leukemia: long-term results of the randomized trial Moscow-Berlin 2002.
Karachunskiy A, Tallen G, Roumiantseva J, Lagoiko S, Chervova A, von Stackelberg A, Aleinikova O, Bydanov O, Bajdun L, Nasedkina T, Korepanova N, Kuznetsov S, Novichkova G, Goroshkova M, Litvinov D, Myakova N, Ponomareva N, Inyushkina E, Kondratchik K, Abugova J, Fechina L, Arakaev O, Karelin A, Lebedev V, Judina N, Scharapova G, Spichak I, Shamardina A, Ryskal O, Shapochnik A, Rumjanzew A, Boos J, Henze G; ALL-MB study group. Karachunskiy A, et al. J Cancer Res Clin Oncol. 2019 Apr;145(4):1001-1012. doi: 10.1007/s00432-019-02854-x. Epub 2019 Mar 6. J Cancer Res Clin Oncol. 2019. PMID: 30840197 Free PMC article. Clinical Trial.
Prognostic value of minimal residual disease measured by flow-cytometry in two cohorts of infants with acute lymphoblastic leukemia treated according to either MLL-Baby or Interfant protocols.
Popov A, Buldini B, De Lorenzo P, Disarò S, Verzhbitskaya T, Movchan L, Giarin E, Shorikov E, Di Meglio A, Tsaur G, Parasole R, Miakova N, Boichenko E, Kondratchik K, Aleinikova O, Karachunskiy A, Roumiantsev A, Locatelli F, Biondi A, Pieters R, Valsecchi MG, Fechina L, Basso G. Popov A, et al. Among authors: karachunskiy a. Leukemia. 2020 Nov;34(11):3042-3046. doi: 10.1038/s41375-020-0912-z. Epub 2020 Jun 12. Leukemia. 2020. PMID: 32533093 No abstract available.
Prognostic value of minimal residual disease measured by fusion-gene transcript in infants with KMT2A-rearranged acute lymphoblastic leukaemia treated according to the MLL-Baby protocol.
Tsaur G, Popov A, Riger T, Kustanovich A, Solodovnikov A, Shorikov E, Demina A, Verzhbitskaya T, Streneva O, Makarova O, Lapotentova E, Aleinikova O, Miakova N, Boichenko E, Kondratchik K, Ponomareva N, Karachunskiy A, Roumiantsev A, Fechina L. Tsaur G, et al. Among authors: karachunskiy a. Br J Haematol. 2021 Jun;193(6):1151-1156. doi: 10.1111/bjh.17304. Epub 2021 Feb 14. Br J Haematol. 2021. PMID: 33583020 Clinical Trial.
The use of additional immunophenotypic criteria for the differential diagnosis of Burkitt lymphoma/leukemia: An exemplary case report.
Demina I, Zerkalenkova E, Zhogov V, Lagoyko S, Semchenkova A, Dubrovina M, Volchkov E, Olshanskaya Y, Mikhailova E, Samochatova E, Karachunskiy A, Novichkova G, Miakova N, Maschan A, Popov A. Demina I, et al. Among authors: karachunskiy a. Leuk Res. 2021 Nov;110:106662. doi: 10.1016/j.leukres.2021.106662. Epub 2021 Jul 2. Leuk Res. 2021. PMID: 34242914 No abstract available.
Strong expansion of normal CD19-negative B-cell precursors after the use of blinatumomab in the first-line therapy of acute lymphoblastic leukaemia in children.
Mikhailova E, Roumiantseva J, Illarionova O, Lagoyko S, Miakova N, Zerkalenkova E, Zharikova L, Olshanskaya Y, Novichkova G, Maschan M, Henze G, Karachunskiy A, Popov A. Mikhailova E, et al. Among authors: karachunskiy a. Br J Haematol. 2022 Jan;196(1):e6-e9. doi: 10.1111/bjh.17760. Epub 2021 Aug 3. Br J Haematol. 2022. PMID: 34346071 No abstract available.
26 results